This study is for people with a type of blood cancer called acute myeloid leukemia (AML). The study is testing different ways to treat AML for patients who have not yet been treated and are considered "high-risk," meaning their AML is tough to treat. In this study, researchers will compare the usual treatment, which is a medicine combination called cytarabine and daunorubicin, to new treatments. These new treatments add medicines like venetoclax and azacitidine to see if they work better at stopping the cancer.

• The study lasts for up to 5 years, with regular check-ups needed.
• Participants must be between ages 18-59 and have not been treated for AML before.
• There are potential risks, like side effects from the medicines.

Participants will receive one of the treatments and will have tests like blood samples and heart checks during the study. After treatment, they will have follow-up visits for several years. You can join if you've been diagnosed with high-risk AML and meet other health criteria. Talk to your doctor to see if this study is right for you.